592 related articles for article (PubMed ID: 9556058)
1. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
[TBL] [Abstract][Full Text] [Related]
2. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
van beek E; Löwik C; van der Pluijm G; Papapoulos S
J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
[TBL] [Abstract][Full Text] [Related]
3. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
Fisher JE; Rogers MJ; Halasy JM; Luckman SP; Hughes DE; Masarachia PJ; Wesolowski G; Russell RG; Rodan GA; Reszka AA
Proc Natl Acad Sci U S A; 1999 Jan; 96(1):133-8. PubMed ID: 9874784
[TBL] [Abstract][Full Text] [Related]
4. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
Frith JC; Rogers MJ
J Bone Miner Res; 2003 Feb; 18(2):204-12. PubMed ID: 12568397
[TBL] [Abstract][Full Text] [Related]
5. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.
Luckman SP; Coxon FP; Ebetino FH; Russell RG; Rogers MJ
J Bone Miner Res; 1998 Nov; 13(11):1668-78. PubMed ID: 9797474
[TBL] [Abstract][Full Text] [Related]
6. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase.
Reszka AA; Halasy-Nagy JM; Masarachia PJ; Rodan GA
J Biol Chem; 1999 Dec; 274(49):34967-73. PubMed ID: 10574973
[TBL] [Abstract][Full Text] [Related]
8. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
Fisher JE; Rodan GA; Reszka AA
Endocrinology; 2000 Dec; 141(12):4793-6. PubMed ID: 11108295
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG; Rogers MJ
Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
[TBL] [Abstract][Full Text] [Related]
12. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
13. JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, number 4, pp 581-9 (1998).
Luckman SP; Hughes DE; Coxon FP; Russell GG; Rogers MJ
J Bone Miner Res; 2005 Jul; 20(7):1265-74. PubMed ID: 16050006
[No Abstract] [Full Text] [Related]
14. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs.
Coxon FP; Benford HL; Russell RG; Rogers MJ
Mol Pharmacol; 1998 Oct; 54(4):631-8. PubMed ID: 9765505
[TBL] [Abstract][Full Text] [Related]
15. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.
Benford HL; McGowan NW; Helfrich MH; Nuttall ME; Rogers MJ
Bone; 2001 May; 28(5):465-73. PubMed ID: 11344045
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates: the first 40 years.
Russell RG
Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages.
Coxon FP; Helfrich MH; Larijani B; Muzylak M; Dunford JE; Marshall D; McKinnon AD; Nesbitt SA; Horton MA; Seabra MC; Ebetino FH; Rogers MJ
J Biol Chem; 2001 Dec; 276(51):48213-22. PubMed ID: 11581260
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.
Halasy-Nagy JM; Rodan GA; Reszka AA
Bone; 2001 Dec; 29(6):553-9. PubMed ID: 11728926
[TBL] [Abstract][Full Text] [Related]
19. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
[TBL] [Abstract][Full Text] [Related]
20. New insights into the molecular mechanisms of action of bisphosphonates.
Rogers MJ
Curr Pharm Des; 2003; 9(32):2643-58. PubMed ID: 14529538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
